Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Protalix Biotherapeutics, Inc. on January 4, 2016. The filing pertains to Item 5.08, Shareholder Director Nominations, and announces the scheduling of the Company's 2016 Annual Meeting of Shareholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural notification regarding corporate governance and does not contain financial performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this document. The primary event is the establishment of dates for the upcoming Annual Meeting.
Guidance, Outlook, and Corporate Actions
- Annual Meeting Date: Scheduled for May 8, 2016.
- Record Date: Fixed as March 10, 2016, for shareholders entitled to receive notice and vote.
- Proposal Deadline: Shareholder proposals must be received by March 14, 2016, at the Company's principal executive offices in Carmiel, Israel.
- Proxy Statement: The Company plans to file and mail a proxy statement containing important information to shareholders.
- Participants: The Company, its directors, and named executive officers may be deemed participants in the solicitation of shareholders.
Key Facts for Investor Verification
- Verify the final date of the Annual Meeting once the proxy statement is filed.
- Confirm the March 10, 2016 record date to ensure eligibility to vote.
- Note the March 14, 2016 deadline for submitting shareholder proposals.
- Review the upcoming proxy statement for details on director nominations and executive compensation.